Global Statistics Representing Diabetic Ketoacidosis Treatment Market Scenario
Diabetic ketoacidosis (DKA) is a serious hyperglycemic emergency in people with diabetes. In this complication, body starts to run out of insulin and produces high level of ketones. As a result, DKA changes chemical balance of blood and can lead to death if not treated on time. It mainly affects people with type 1 diabetes. The condition is triggered either by illness or mismanaged insulin doses and can be treated by using fluids, electrolyte, and insulin therapy. In addition, it can be prevented by monitoring blood sugar level and proper insulin dosage regularly. As per the UK National Diabetes report, around 4% of people suffering from type I diabetes develop DKA. To cover the condition, monitored delivery of intravenous fluids and insulins is provided. Replacing fluid loss, decreasing blood glucose, and reversing acidosis are the main priorities of the care. In addition, unregulated insulin dosages are one of the major causes that lead to DKA. As per the National Pediatric Diabetes Audit 2017, 27% increased risk of admission of Diabetic Ketoacidosis Treatment are associated with insulin pumps than the insulin injections.
Global diabetic ketoacidosis treatment market was valued at USD 1,159.54 million in 2018, growing at a CAGR of 5.6% during the forecast period of 2019–2026.
Increasing Prevalence of Diabetic Ketoacidosis with Type 1 Diabetes
People with diabetes require access to systematic, regular, and organized healthcare from skilled providers. Diabetic ketoacidosis mainly occurs in patients having type 1 diabetes. Despite advancements in self-care of patients with diabetes, DKA is a life-threatening complication and affects around 30 million people in the U.S. In addition, studies have reported that patients that use insulin pumps are more prone to develop DKA and it is more common in young children and adolescents suffering from type 1 diabetes. Almost 50% of diabetes-related admissions in the young population are related to DKA. There has been a rise in cases of DKA with diabetes. As per the CDC report, 168,000 cases were reported for diabetic ketoacidosis in 2014.
For a better understanding of the global diabetic ketoacidosis treatment market, we have segmented the market by type, and end user.
By type, the market is segmented into fluid replacement, electrolyte replacement and insulin therapy. Insulin therapy is accounting for the major market share, growing at a CAGR of 5.9% in the forecast period. Insulin reverses the processes that cause excessive ketones to be released in the blood. Along with the fluids and electrolytes, insulin therapy is provided in diabetic ketoacidosis. However, it is administrated after fluid replacement. Whereas, electrolytes are required for proper functioning of tissue. The absence of insulin during diabetic ketoacidosis can lower the level of several electrolytes in the blood. In case of hypokalemia, fluids and potassium replacement is advised before starting insulin because the insulin administration may drop potassium level further.
Global diabetic ketoacidosis treatment market by Americas, Asia Pacific, Europe, and the Middle East and Africa.
North America is dominating the market and accounted for the highest share in the forecast period. Diabetes and its various related complications such as diabetic ketoacidosis (DKA) put an economic burden on people. It has been observed that the prevalence of DKA is increasing in the patients having type 1 diabetes in the U.S. For instance, National Diabetes Statistics has estimated that about 168,000 cases were diagnosed with diabetic ketoacidosis in 2017. Higher healthcare expenditure and strong penetration of insurance policies covering diabetes and its complications are fueling the market growth. As per the American Diabetes Association, the total cost of diagnosed diabetes reached USD 327 billion in 2017 from USD 245 billion in 2012, out of which around 67.3% cost is covered by the government insurance.
Europe is the second leading region in the forecast period owing to poor diabetic management. Poor diabetic control is one of the major factors responsible for increased risk of diabetic ketoacidosis in the region. This is followed by the use of insulin pumps, which further increases the rate of hospitalization in patients with DKA. As per Diabetes UK, around 2,200 people suffered from diabetic ketoacidosis (DKA) as a result of insulin treatment in 2017. Increasing diabetes-related admissions of children and young people are also increasing cases related to its complications. For instance, during 2014–2015, approximately 40% of DKA admissions were observed within a year of diabetes diagnosis in the U.K.
Some of the prominent players in the market are Novo Nordisk and Biocon. Diabetic ketoacidosis treatment market has very few players. Novo Nordisk and Biocon are two major players providing treatment for the indication. For instance, Biocon offers Human Insulin, which is used for treating of type 1 diabetes mellitus, type 2 diabetes mellitus, diabetic ketoacidosis, and other associated indications. It involves the use of two types of insulin once or many times in a day depending on the condition.
Diabetic Ketoacidosis Treatment Market Segmentation
By End User
Frequently Asked Questions (FAQs)